1. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study
   Sheng-Long Ye et al, 2016, Oncotarget CrossRef
2. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
   Lin Li et al, 2018, BMC Gastroenterology CrossRef
3. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib
   Lei Liu et al, 2019, Canadian Journal of Gastroenterology and Hepatology CrossRef
4. Nonsurgical Treatment for Localised Hepatocellular Carcinoma
   Andrew Kennedy, 2016, EMJ Hepatology CrossRef
5. MicroRNA Gene Polymorphisms in Evaluating Therapeutic Efficacy After Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma
   Guang-Ping Qiu et al, 2016, Genetic Testing and Molecular Biomarkers CrossRef
6. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development
   Xin Li et al, 2021, Frontiers in Molecular Biosciences CrossRef
7. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
   Rong-Ce Zhao et al, 2017, Hepatobiliary & Pancreatic Diseases International CrossRef
8. Role of locoregional therapies in the wake of systemic therapy
   Daniel H. Palmer et al, 2020, Journal of Hepatology CrossRef
9. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
   Ping Wang et al, 2018, Expert Review of Gastroenterology & Hepatology CrossRef
10. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
    Shigeo Shimose et al, 2020, Cancers CrossRef
11. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
    Ying Wu et al, 2020, Frontiers in Pharmacology CrossRef